Resonant to Present at Upcoming Investor Conferences in November
AUSTIN, Texas, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Resonant Inc. (NASDAQ: RESN), a provider of radio frequency (RF) filter solutions...
AUSTIN, Texas, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Resonant Inc. (NASDAQ: RESN), a provider of radio frequency (RF) filter solutions...
JUPITER, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),...
Supply agreement enables development of POINT’s next-generation Ac-225-based radioligand therapies.INDIANAPOLIS and TORONTO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma...
Safety and tolerability of new liposomal IV formulation confirmed to reach target exposure in single ascending dose (SAD) and multiple...
CALGARY, Alberta, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Maple Leaf Green World Inc. (“Maple Leaf” or the “Company”), (CSE: MGW)...
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically...
PLEASANTON, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Healthcare Triangle Inc., (Nasdaq: HCTI) (“HCTI” or the "Company"), a leading provider...
HIGH POINT, N.C., Nov. 09, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third...
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today...
NEWPORT BEACH, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric...
BRENTWOOD, Tenn., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (Nasdaq: SGRY) (“Surgery Partners”) today announced the pricing of...
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that...
HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced the presentation...
Data from Phase IIb AIPAC, including final Overall Survival data, reported in a separate announcementEncouraging Objective Response Rate (ORR) of...
Findings provide key insights into ATYR2810’s potential mechanism of action, including ability to modulate key immune cells involved in tumor...
PRESS RELEASE RESS RELEASE Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at...
LEXINGTON, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of...
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baselineBatiraxcept has been...
$2.5 Million in Annualized Revenues, 25% Projected Adjusted EBITDA Margin Post Integration, and Adds Over 3,700 Active Patients Quipt Has...
- Oral Presentation at European Society for Gene and Cell Therapy (ESGCT) demonstrated ability to generate potent anti-cancer cell therapy...